药物发现和开发的基本原则

关键字：类型：

下载页码(大于0,小于537)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)

green fluorescent protein (GFP),170–171 170 171

membrane potentials and ion channels, 169–170 169 170

yellow fluorescent protein (YFP),170–171 170 171

Time-resolved fluorescence resonance

energy transfer (TRFRET)

Allophycocyanin, 173–174 173 174

background fluorescence, 172–173,173f 172 173 173

downstream cellular activity, 174–175,174f 174 175 174

GPCR signaling pathway, 174–175 174 175

kinase activity, 173–174, 173f 173 174 173

lanthanide-based fluorophores,172–173, 172f 172 173 172

Fluorescent Imaging Plate Reader (FLIPR),184–185 184 185

Food, Drug, and Cosmetic Act, 383 383

Forced swimming test, 315, 315f 315 315

Formulation, 391–395 391 395

excipients, 391–393, 392t 391 393 392

antiadherents, 391–392, 392t 391 392 392

colorants and antioxidants, 391–392 391 392

disintegrants, 392, 392t 392 392

dry binders fillers, 392t 392

glidants, 391–392, 392t 391 392 392

drug supply, 387f. See also Drug supply 387

formulation. See Formulation

patient randomization, 385 385

phase I, 9–10, 397–398, 398f 9 10 397 398 398

dose limiting toxicities (DLT), 397,398f 397 398

maximum tolerated dose (MTD),397–398, 398f 397 398 398

multiple ascending dose (MAD) study,397–398 397 398

NOAEL (no observed adverse effect level), 397 397

single ascending dose (SAD) study,397–398 397 398

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：